Literature DB >> 34362229

Asthma, Allergic Rhinitis, and Atopic Dermatitis Incidence in Korean Adolescents before and after COVID-19.

Hyo Geun Choi1,2, Il Gyu Kong3.   

Abstract

With changes in personal habits (masks and handwashing) during the COVID-19 outbreak, the study analyzed the reporting of physician-diagnosed cases (incidence) of allergic diseases (asthma, allergic rhinitis, and atopic dermatitis) using the data for years 2019 and 2020 from the Korean adolescent risk behavior web-based survey (KYRBWS-15 and 16). Altogether, 92,659 adolescents (48,443 in 2019 and 44,216 in 2020) were enrolled. The crude and adjusted odd ratios (ORs) were calculated for each disease in 2020 compared to that in 2019 using multiple logistic regression. Subgroup analyses were performed according to sex and economic status. The incidence of asthma decreased from 1.5% in 2019 to 1.0% 2020 (p < 0.001). The incidence of allergic rhinitis in 2019 and 2020 was 19.5% and 16.3%, respectively (p < 0.001). Compared with 2019, the adjusted OR (aOR) in 2020 was 0.68 (95% CI = 0.66-0.77, p value < 0.001) for asthma and 0.82 (95% CI = 0.78-0.85, p < 0.001) for allergic rhinitis. In contrast, there was no statistically significant difference between the incidence of atopic dermatitis in 2019 and that in 2020 (6.4%, vs. 6.4%, p > 0.05, respectively). Subgroup analyses results were consistent. In conclusion, there was decrease in the incidence of asthma and allergic rhinitis but not in that of atopic dermatitis from 2019 to 2020.

Entities:  

Keywords:  COVID-19; allergic rhinitis; asthma; atopic dermatitis; coronavirus; cross-sectional studies; incidence; pandemic

Year:  2021        PMID: 34362229     DOI: 10.3390/jcm10153446

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  1 in total

1.  Facial dermatoses and use of protective mask during Covid-19 pandemic: A clinical and psychological evaluation in patients affected by moderate-severe atopic dermatitis under treatment with dupilumab.

Authors:  Mazzoletti Vanessa; Esposto Elia; Veronese Federica; Cammarata Edoardo; Airoldi Chiara; Graziola Francesca; Savoia Paola
Journal:  Dermatol Ther       Date:  2022-05-22       Impact factor: 3.858

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.